SecBot SecBot
6-K ·Filed Jun 2, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001178913-26-003058
Notable filing: 6-K
Actionable Insight • Neutral

Routine board and committee reshuffling with no operational or strategic catalysts. No trading implications, monitor upcoming pipeline updates or financial filings for material events.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.72
T+0 close · Jun 2, 2026 · via day close
Latest settled
+58.14%
T+60 · $2.72
Vs SPY
+55.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $1.72entry
  2. T+1 · 6mo ago +4.65%α +4.25% · $1.80
  3. T+5 · 5mo ago +1.74%α +5.56% · $1.75
  4. T+20 · 5mo ago +31.98%α +32.98% · $2.27
  5. T+60 · 3mo ago +58.14%α +55.64% · $2.72

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance committee, replacing Claude Nicaise and Jill Quigley who resigned without disagreement. The board also shuffled audit committee members. These are routine governance changes with no material financial or strategic impact.

Key Facts

  • Gwen Melincoff appointed as Class I Director and chair of nominating and governance committee, effective June 1, 2026
  • Claude Nicaise resigned as director and audit committee member on May 29, 2026
  • Jill Quigley resigned as director and audit committee member on May 29, 2026
  • Neither resignation was due to any disagreement with the company
  • Neil Cohen and Nissim Darvish appointed to audit committee on June 1, 2026
  • Neil Cohen resigned as nominating committee chair, replaced by Gwen Melincoff
  • Board size set at five directors

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • No identified risks from this filing, routine governance changes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-003058
Document: 0001178913-26-003058-index-headers.html0001178913-26-003058
Document: 0001178913-26-003058-index.html0001178913-26-003058
Document: 0001178913-26-003058.txt0001178913-26-003058

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026